...
首页> 外文期刊>The Journal of Pharmacology and Experimental Therapeutics: Official Publication of the American Society for Pharmacology and Experimental Therapeutics >Modeling Corticosteroid Pharmacokinetics and Pharmacodynamics, Part III: Estrous Cycle and Estrogen Receptor-Dependent Antagonism of Glucocorticoid-Induced Leucine Zipper (GILZ) Enhancement by Corticosteroids
【24h】

Modeling Corticosteroid Pharmacokinetics and Pharmacodynamics, Part III: Estrous Cycle and Estrogen Receptor-Dependent Antagonism of Glucocorticoid-Induced Leucine Zipper (GILZ) Enhancement by Corticosteroids

机译:模拟皮质类固醇药代动力学和药效学,第III部分:糖皮质激素诱导的糖皮质激素诱导亮氨酸拉链(GILZ)提高皮质类固醇的雌激素循环和雌激素受体依赖性拮抗作用

获取原文
获取原文并翻译 | 示例
           

摘要

Our previous report examined the pharmacokinetics (PK) of methylprednisolone (MPL) and adrenal suppression after a 50 mg/kg IM bolus in male and female rats, and we described in detail the development of a minimal physiologically based pharmacokinetic/pharmacodynamic (mPBPK/PD) model. In continuation of such assessments, we investigated sex differences in genomic MPL responses (PD). Message expression of the glucocorticoid-induced leucine zipper (GILZ) was chosen as a multitissue biomarker of glucocorticoid receptor (GR)-mediated drug response. Potential time-dependent interplay between sex hormone and glucocorticoid signaling in vivo was assessed by comparing the enhancement of GILZ by MPL in the uterus [high estrogen receptor (ER) density] and in liver (lower ER density) from male and female rats dosed within the proestrus (high estradiol/progesterone) and estrus (low estradiol/progesterone) phases of the rodent estrous cycle. An expanded-systems PD model of MPL considering circadian rhythms, multireceptor (ER and GR) control, and estrous variations delineated the determinants controlling receptor/gene-mediated steroid responses. Hepatic GILZ response was similar to 3-fold greater in females, regardless of estrous stage, compared with males, driven predominantly by increased MPL exposure in females and a negligible influence of estrogen interaction. In contrast, GILZ response in the uterus during proestrus in females was 60% of that observed in estrus-phased females, despite no PK or receptor differences, providing in vivo support to the hypothesis of estrogen-mediated antagonism of glucocorticoid signaling. The developed model offers a mechanistic platform to assess the determinants of sex and tissue specificity in corticosteroid actions and, in turn, reveals a unique PD drug-hormone interaction occurring in vivo.
机译:我们之前的报告检测了甲基己酮(MPL)(MPL)的药代动力学(PK)和在雄性和雌性大鼠中50mg / kg IM推注后的肾上腺抑制,并详细描述了最小的生理基础药代动力学/药物动力学的发育(MPBPK / PD ) 模型。在继续这种评估中,我们研究了基因组MPL反应(PD)的性差异。选择糖皮质激素诱导的亮氨酸拉链(GILZ)的消息表达作为糖皮质激素受体(GR)介导的药物反应的多毒性生物标志物。通过在子宫中的[高雌激素受体(ER)密度]和肝脏(较低的雌性大鼠中,通过比较MPL中的GILZ的增强来评估性激素和糖皮质激素信号传导中的潜在时间依赖性相互作用。啮齿动物溶解循环的前塞(高雌二醇/黄体酮)和雌激素(低雌二醇/黄体酮)阶段。考虑昼夜节律,多人(ER和GR)控制和溶解的系统的MPL扩展系统PD模型描绘了控制受体/基因介导的类固醇反应的决定因素。肝脏Gilz反应在女性中与3倍较高,无论雌性阶段如何,与雄性相比,主要通过女性的MPL暴露和雌激素相互作用的忽略影响而导致。相反,除了PK或受体差异的女性中,女性在女性中观察到的子宫内的GILZ反应是60%,只有PK或受体差异,提供了对糖糖皮质激素信号传导的雌激素介导的拮抗作用的假设的支持。开发的模型提供了机械平台,以评估皮质类固醇作用中性别和组织特异性的决定因素,又揭示了体内发生的独特的PD药物 - 激素相互作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号